Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection

Published:2020-04-22 Issue:5 Volume:37 Page:2493-2506
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Liu Kaiyan,Wu Depei,Li Junmin,Chen Hu,Ning Hongmei,Zhao Ting,Dai Haiping,Chen Li,Mangin Eric,Winchell Gregory A.,Waskin Hetty,Jiang Jun,Qiu Yanping,Zhao Xu Min

Funder

Merck Sharp & Dohme

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-020-01341-x.pdf

Reference48 articles.

1. Keating GM. Posaconazole. Drugs. 2005;65(11):1553–677.

2. Lien MY, Chou CH, Lin CC, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study. PLoS One. 2018;13(6):e0197851.

3. Xu XH, Zhang L, Cao XX, et al. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. J Infect Chemother. 2017;23(6):360–7.

4. Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol. 2015;36(2):757–67.

5. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–96.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Posaconazole enteric-coated tablets on the efficacy and tolerability of secondary antifungal prophylaxis in haploidentical allogeneic stem cell transplantation;2024-08-10

2. An update on the global treatment of invasive fungal infections;Future Microbiology;2023-11

3. Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection;The Journal of Clinical Pharmacology;2022-12

4. Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China;Frontiers in Public Health;2022-05-17

5. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections;Advances in Therapy;2022-02-15